Dr. Howard Verrico reports

SIRONA BIOCHEM ADVANCES SKIN LIGHTENER TFC-1067 DEVELOPMENT AND IP PROTECTION IN ANTICIPATION OF LICENSING DISCUSSIONS

Sirona Biochem Corp. has advanced the commercial development and IP (intellectual property) protection of its novel skin lightening agent TFC-1067.

As part of Sirona's continued commercialization efforts, the scientific team has engaged consultant Gael Boutry (Global Beauty Consulting) to create the next-generation formulation of TFC-1067. Sirona's first formulation was a simplified design for use in its current clinical trial. The primary objective was to demonstrate the efficacy of TFC-1067 without any enhancers.

The new formulation has been developed in order to maximize the efficacy of TFC-1067 through the synergic effect of different actives. The target is to combine a faster effect by acting on cell renewal and a stronger depigmenting/lightening effect by acting on different pathways. TFC-1067 has shown scientifically to safely inhibit new pigmentation formation in the melanocyte skin cells by inhibiting a key enzyme called tyrosinase. Stimulating cell renewal through exfoliation of the most superficial skin layer will shorten the normal skin renewal cycle with a goal to obtain visible results quicker. Other approaches on the melanocyte's development could provide a synergic effect with TFC-1067 and lead to stronger efficacy.

The process of optimally formulating TFC-1067 is a necessary step prior to a commercial launch of this type of active. The formulation will undergo testing to demonstrate stability as well as human patch testing to demonstrate that it is a non-irritant. While waiting for the results of the clinical trial now under way, the team is simultaneously working on these steps with the goal to optimize the current product's commercial value while also shortening the time to commercialization.

Sirona has also continued to expand patent coverage of TFC-1067 and the seven other compounds which make up the family of skin lightening agents.

One filed patent has entered the European phase and the company has now formally selected key European countries to specifically patent protect its family of skin lighteners. Another patent has entered the PCT phase where key countries have been selected as the major world markets. Sirona currently has nine patents filed in multiple key markets to maximize the commercial value of its novel compounds and wide range of therapeutic and cosmetic applications. Sirona has taken great care to patent not only its key discoveries but also the related family of compounds to help protect its IP from competitors.

"We are excited to be able to continually innovate while aggressively protecting our innovations through strong patents. Having our own dedicated lab with a successful scientific team and having the services of a leading biotechnology patent firm Regimbeau of Paris has enabled us to steadily grow the commercial value of our technology," reported Dr. Howard Verrico, chief executive officer. "We are also fortunate to have world-class consultants like Gael Boutry providing necessary specialized expertise as well as the ongoing financial support of the French government and European Union while we work towards becoming financially self-sufficient. We feel well prepared to enter anticipated licensing discussions at the completion of our current skin lightening clinical trial as a next step towards being part of the $20-billion (U.S.) global skin lightening market."

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and continuing royalty payments.

We seek Safe Harbor.